Please login to the form below
Communiqué - Volume 36
Communiqué 36 is available to view online now, but if you don't currently receive Communiqué on a regular basis you can subscribe to the print or digital edition - or keep up with pharma news on a more regular basis via our PMLiVE Daily or Weekly email newsletters.
Register here to receive email notification of future digital editions of Communiqué or contact the subscriptions department to enquire about receiving a print copy of the magazine. More PMLiVE digital editions can be found here.
Communiqué is also available to download as an app for iPhone and iPad
Please note: Some older digital editions may no longer be accessible while we transition to a new digital edition system and app - www.pmlive.com/pme?category=communiqué
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- Moderna’s Omicron booster receives MHRA approval
- Lack of evidence for AstraZeneca’s COVID-19 vaccine says UK Department of Health
- NHS England outlines measures to boost capacity ahead of substantial winter pressures
- New research shows drug candidate may effectively treat antibiotic-resistant bacteria
- Sanofi and NIHR enrol first patient in immunisation study for RSV in infants
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Roche shares new positive Ocrevus data for MS patients
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- bluebird bio reveals plans to launch two gene therapies
- NHS App to revolutionise digital health and care with major digital updates by 2023
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
